L
Limin Liu
Researcher at Soochow University (Suzhou)
Publications - 33
Citations - 181
Limin Liu is an academic researcher from Soochow University (Suzhou). The author has contributed to research in topics: Hematopoietic stem cell transplantation & Transplantation. The author has an hindex of 6, co-authored 25 publications receiving 104 citations. Previous affiliations of Limin Liu include Xuzhou Medical College.
Papers
More filters
Journal ArticleDOI
Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia
Limin Liu,Yanming Zhang,Wenjing Jiao,Huifen Zhou,Qingyuan Wang,Song Jin,Yifeng Cai,Liyun Zhao,Xiaohui Shangguan,Zefa Liu,Jinge Xu,Meiqing Lei,Xiaoyun Yan,Miao Miao,Depei Wu +14 more
TL;DR: First-line haplo-HSCT combined with UCB infusion might provide a better chance of success and HRQoL than first-line IST for SAA patients, suggests retrospectively compared the efficacy and health-related quality of life of these patients.
Journal ArticleDOI
Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia.
Limin Liu,Limin Liu,Li Ding,Lin Hao,Xingxia Zhang,Xiaoli Li,Liansheng Zhang,Zhengdong Hao,Meiqing Lei,Yanming Zhang,Depei Wu +10 more
TL;DR: In this article, a comparison of the efficacy of porcine immunoglobulin (pALG) and rabbit ATG (rATG) as a first-line treatment for acquired SAA has not been reported.
Journal ArticleDOI
Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia
Limin Liu,Yanming Zhang,Zhengming Jin,Xingxia Zhang,Guang-sheng Zhao,Yejun Si,Guoqiang Lin,Aidi Ma,Yingxin Sun,Li Wang,Depei Wu +10 more
TL;DR: Increasing the dose of aclarubicin in CAG regimen can be used safely and effectively in the treatment of relapsed or refractory AML.
Journal ArticleDOI
Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
TL;DR: HD-CAG can safely improve efficacy compared to the CAG regimen and thus serves as an alternative treatment for R/R AML.
Journal ArticleDOI
Excellent Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Study
Limin Liu,Shan Liu,Yanming Zhang,Huifen Zhou,Qingyuan Wang,Hong Tian,Feng Chen,Huiying Qiu,Xiaowen Tang,Yue Han,Chengcheng Fu,Zhengming Jin,Suning Chen,Aining Sun,Miao Miao,Depei Wu +15 more
TL;DR: The preliminary results indicated that allo-HSCT is a feasible option for patients with PNH; however, this should not be considered as a first-choice therapy, because the results seemed to only suggest rather than confirm that haplo- HSCT and MSD-HS CT exerted similar therapeutic efficacies.